MAY 25, 2020 9:59 AM PDT

Using Transcription Factors to Predict Bladder Cancer Prognosis

WRITTEN BY: Jasper Cantrell

Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, with around half of patients affected. Prognostic tests can help identify patients who have a high likelihood of recurrence before it occurs. Using this information, doctors can take preventative measures and increase the overall survival rate of patients.

A team from Taiwan decided to tackle this task, focusing on identifying possible transcription factors that might influence tumor progression. Previous work has shown transcription factors tied to the differentiation of cells in adults may also have pro-tumor effects. They analyzed a series of these transcription factors in bladder cancer to identify any that correlate with recurrence-free survival (RFS). Sex determining region Y box-2 (SOX2) was found to be the only transcription factor tested that had a strong correlation.

Normally SOX2 is a transcription factor involved in the maintenance of undifferentiated cells. It had been implicated in recent work to be a possible pro-tumor factor in some cancers. SOX2 was tested to identify its role in cell survival using two bladder cancer cell lines, one with high SOX2 expression and one with low expression. They found that a low SOX2 expression led to a reduction in cellular proliferation. Following this discovery, they focused their testing on the AKT pathway and if SOX2 affected it. This pathway is involved in cellular proliferation, and its abnormal activation is common in many cancers. The analysis showed that high levels of SOX2 correlated with high levels of AKT activation in bladder cancer.

The group then examined the genetic expression of SOX2 overexpressing bladder cancer cells versus normal expressing bladder cancer cells. Insulin like growth factor 2 (IGF2), a peptide hormone whose overexpression in other cancers is linked to an aggressive phenotype, was found to increase and decrease with SOX2 levels. Importantly, IGF2 signaling was vital in the cellular proliferation affects SOX2 generated. This effectively connects SOX2 to two separate pro-tumor factors, AKT activation, and IGF2 levels, which make it a good target for further biomarker studies.

This work identified SOX2 as a possible biomarker that can be used to predict the prognosis of bladder cancer patients. Furthermore, SOX2’s connection to both AKT and IGF2 makes it a potential therapeutic target for future research. SOX2 is already being studied in several other cancers, including lung and breast cancers. With further investigation, it may prove to be a good target for prognostic tests and increase the survival of patients diagnosed with bladder cancer.

Sources: Nature, Cell Signaling Technologies, Inc.

 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
APR 21, 2020
Clinical & Molecular DX
APR 21, 2020
Skin Deep: Handheld Device Sees the Earliest Signs of Cancer
Researchers have developed a handheld device that can image structures under the skin at resolutions 100 times greater t ...
APR 23, 2020
Cancer
APR 23, 2020
Dual Inhibition from One Chemotherapy
Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary targets of chemo ...
MAY 10, 2020
Genetics & Genomics
MAY 10, 2020
Towards a Targeted Elimination of Leukemic Cells
Our blood carries many types of critical cells, including platelets, red blood cells, and white blood cells, which are m ...
MAY 05, 2020
Cancer
MAY 05, 2020
Can a face-aging app improve sun protection behavior?
Can a face-aging mobile app improve the skin cancer protection behavior of teenagers? A cluster-randomized clinical tria ...
JUN 08, 2020
Cancer
JUN 08, 2020
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD- ...
JUN 25, 2020
Cancer
JUN 25, 2020
Examining the Glioma Influenced Immune System
The human body is a complicated network of systems and signals.  Many systems regulate themselves or others in vari ...
Loading Comments...